Welcome to our dedicated page for Elanco Animal Health news (Ticker: ELAN), a resource for investors and traders seeking the latest updates and insights on Elanco Animal Health stock.
Elanco Animal Health Incorporated (NYSE: ELAN) is a global animal health company focused on products and services that prevent and treat disease in farm animals and pets. The ELAN news feed on Stock Titan aggregates company announcements, regulatory updates and other disclosures so readers can follow how Elanco’s strategy and product portfolio evolve over time.
Elanco regularly issues news on pet health innovations, including prescription products for dogs and cats. Recent press releases have covered developments in canine dermatology, such as Zenrelia tablets for control of itching and inflammation associated with skin allergies in dogs and Befrena, an injectable monoclonal antibody targeting canine allergic and atopic dermatitis. The company also reports on its Credelio and Credelio Quattro brands for parasite control in dogs and Credelio CAT for cats, including label expansions, emergency use authorizations and new indications such as protection related to Lyme disease and emerging tick species.
Investors and industry followers will also find farm animal and corporate updates, including quarterly financial results, guidance, restructuring plans and productivity initiatives like Elanco Ascend. News items describe trends in pet health and farm animal revenue, progress in innovation pipelines, changes to manufacturing and R&D footprints, and participation in major healthcare and investor conferences.
This ELAN news page helps readers track how Elanco’s innovation, portfolio and productivity strategy is reflected in product approvals, regulatory milestones, financial performance and strategic partnerships. For anyone monitoring animal health markets, veterinary therapeutics or ELAN stock, it provides a centralized view of the company’s most recent public communications.
Summary not available.
Elanco Animal Health Incorporated (NYSE: ELAN) will disclose its first quarter 2023 financial results on May 9, 2023. The company will hold a conference call at 8:00 a.m. eastern time to discuss its performance with investors and media. A live webcast of the call can be accessed via a link on Elanco's website, with a replay available shortly after. Elanco focuses on delivering products and services aimed at preventing and treating diseases in animals. With a legacy of nearly 70 years, the company aims to enhance the health of animals and contribute positively to communities.
Athian, the first cloud-based carbon marketplace for the livestock industry, has secured a seed investment from Tyson Ventures, aiming to enhance sustainability practices in livestock farming. This investment, alongside previous funding from Elanco Animal Health and Newtrient LLC, will expedite the launch of a unique carbon credit inset program designed to reward farmers for measurable greenhouse gas reductions. Athian’s platform is set to go live in the second half of 2023, allowing livestock producers to monetize their sustainability efforts while contributing to climate change mitigation.
Elanco Animal Health Incorporated (NYSE: ELAN) will participate in the Barclays Global Healthcare Conference on March 14-15, 2023. The company's CFO, Todd Young, is set to engage in a fireside chat on March 14 at 8:30 a.m. ET. A live audio webcast of the event can be accessed via the 'Events and Presentations' section on Elanco's investor website, with a replay available for 30 days.
Elanco, a leader in animal health, focuses on innovative solutions for farm animals and pets, committed to improving animal health and community impact.
Elanco Animal Health Incorporated (NYSE: ELAN) will participate in the Cowen 43rd Annual Health Care Conference on March 6-7, 2023. Jeff Simmons, the president and CEO, is scheduled for a fireside chat on March 6 at 2:10 p.m. ET. A live audio webcast will be available in the 'Events and Presentations' section of Elanco's investor website, with a replay available for about 30 days.
Elanco is dedicated to improving animal health, with nearly 70 years of experience in delivering effective products and services for farm animals and pets.
Elanco Animal Health (NYSE: ELAN) will participate in the Bank of America 2023 Animal Health Summit on March 2, 2023, at 4:40 p.m. ET. The event will feature Jeff Simmons, president and CEO, and Todd Young, executive vice president and CFO, who will engage with analysts during the conference.
A live audio webcast of the event will be accessible in the Events and Presentations section of Elanco's investor website and will remain available for replay for 30 days.
Elanco Animal Health reported Q4 2022 revenue of $988 million, an 11% decline year-over-year, with a net loss of $54 million. For the full year, total revenue was $4,418 million, down 7% from 2021. Adjusted net income for Q4 was $95 million, with an adjusted EBITDA margin of 17.6%. The company has guided for 2023 revenues between $4,280 million and $4,400 million and a reported net loss of $157 million to $109 million. Elanco is pursuing FDA approvals for new products expected in early 2024. The company faces ongoing competitive pressures but anticipates sales growth from innovation and pricing.
Elanco Animal Health (NYSE: ELAN) announced the appointment of Tim Bettington as the executive vice president of Corporate Strategy and Market Development, effective March 20. Bettington's role will focus on corporate strategy and market development, particularly in preparing for a significant innovation period and driving growth initiatives for 2025 and beyond. He brings over 25 years of experience in animal health, previously serving at Zoetis and Boehringer Ingelheim. CEO Jeff Simmons emphasized the addition strengthens Elanco's leadership, aimed at enhancing market share and executing successful product launches amidst an exciting pipeline.
Elanco Animal Health Incorporated (NYSE: ELAN) will release its fourth quarter and full year 2022 financial results on February 21, 2023. A conference call is scheduled for 8:00 a.m. eastern time that day, where the company will discuss its performance with investors and media. The call will be accessible via a live webcast posted on Elanco's website, with a replay available shortly after. Elanco is committed to providing innovative animal health products and services aimed at improving the health of farm animals and pets, with nearly 70 years of experience in the field.
Elanco Animal Health (NYSE: ELAN) will participate in the 41st Annual J.P. Morgan Healthcare Conference on January 10, 2023, at 12:45 p.m. ET. The company will be represented by Jeff Simmons, president and CEO, who will address analyst questions during the event.
A live audio webcast will be accessible in the 'Events and Presentations' section of Elanco’s investor website, with a replay available for 30 days.